Figure 1 | Scientific Reports

Figure 1

From: Generation of therapeutic protein variants with the human serum albumin binding capacity via site-specific fatty acid conjugation

Figure 1

Scheme of site-specific palmitic acid-conjugation to urate oxidase (Uox) for acquired human serum albumin (HSA) binding capacity. A clickable non-natural amino acid, p-azido-L-phenylalanine (AzF) is introduced to a specific site of Uox. Palmitic acid analog containing dibenzocyclooctyne group (DBCO-Pal) is conjugated to AzF site of Uox via strain-promoted azide-alkyne cycloaddition (SPAAC). The palmitic acid-conjugated Uox (Uox-Pal) binds HSA, while wild-type Uox (Uox-WT) does not bind HSA. In the structure of Uox, AzF incorporation site and active site, which are marked in blue and red respectively, are distant from each other.

Back to article page